Hims Stock Falls in 2025 After Wegovy Deal Ends
Hims & Hers Health Inc. (NYSE: HIMS) made headlines in June 2025 after pharmaceutical partner Novo Nordisk abruptly terminated its agreement with the company. The partnership focused on the distribution of Wegovy, a weight-loss drug powered by semaglutide, but was cut short due to alleged regulatory concerns and misleading marketing tactics. The news caused Hims … Read more